A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This randomized, open-label study will evaluate the effect of food, and the effect of omeprazole and ranitidine on danoprevir co-administered with ritonavir. Volunteers will be assigned to one of two treatment groups. Volunteers in both groups will receive oral doses of danoprevir and ritonavir. In addition, volunteers in group 2 will receive oral doses of omeprazole and ranitidine. The anticipated time of the study is approximately 6 weeks.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult healthy volunteers, aged 18 to 45 years, inclusive
Weight >/= 50.0 kg
Body Mass Index (BMI) 18.0 to 32.0 kg/m2, inclusive
Presence of any active or chronic disease
Abnormal blood pressure
Abnormal resting heart rate
Abnormal ECG values
History of any clinically significant cardiovascular or cerebrovascular disease
Current smokers or subjects that have discontinued smoking < 6 months prior to first dose of study drug
Positive for hepatitis B, hepatitis C or HIV
Positive test for drugs of abuse or alcohol
Positive result for H. pylori
Regular use of antacids, H-2 blockers, proton pump inhibitors, or any investigational drug within 30 days of first dose of study medication
History of clinically significant gastrointestinal disease